A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study Examining the Efficacy and Safety of Weekly Intramuscular Administration of 15mg Alefacept Over 12 Weeks in a Population of Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
-
-
-
-
-
Brussels, Belgium, 1070
-
Edegem, Belgium, 2650
-
Liege, Belgium, 4020
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T5J 3S9
-
-
Newfoundland and Labrador
-
St. Johns, Newfoundland and Labrador, Canada, A1B 4S8
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1Z4
-
-
Ontario
-
Concord, Ontario, Canada, L4K 5V2
-
Hamilton, Ontario, Canada, L8N 1V6
-
London, Ontario, Canada, N6K 1L6
-
Windsor, Ontario, Canada, N8W 5L7
-
-
Quebec
-
Montreal, Quebec, Canada, H2K 4L5
-
Sainte-Foy, Quebec, Canada, G1V 4X7
-
-
-
-
-
Bochum, Germany, 44791
-
Dresden, Germany, 01307
-
Duesseldorf, Germany, 40225
-
Essen, Germany, 45147
-
Frankfurt, Germany, 60596
-
Goettingen, Germany, 37075
-
Hamburg, Germany, 20246
-
Hannover, Germany, 30449
-
Homburg-Saar, Germany, 66421
-
Mannheim, Germany, 68135
-
Muenster, Germany, 48149
-
-
-
-
California
-
Irvine, California, United States, 92697
-
Santa Monica, California, United States, 90404
-
-
Nebraska
-
Omaha, Nebraska, United States, 68144
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
-
-
North Carolina
-
Winston Salem, North Carolina, United States, 27157
-
-
Tennessee
-
Goodlettsville, Tennessee, United States, 37072
-
-
Texas
-
Dallas, Texas, United States, 75246
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
-
-
Washington
-
Seattle, Washington, United States, 98104
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of Chronic Plaque Psoriasis involving ≥ 10% body surface area
- Treatment history for Psoriasis in which 3 or more conventional anti-psoriatic therapies are inappropriate or ineffective
- CD4+ T lymphocyte counts at or above the lower limit of normal
Exclusion Criteria:
- Clinically significant abnormal hematology values or blood chemistry values
- AST or ALT ≥ 3x the upper limit of normal
- Other types of Psoriasis
- Serious infection within the 3 months prior to the first dose of study drug
- History of drug or alcohol abuse within the past 2 years
- Antibody positive for HIV
- History of malignancy
- History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease
- Exposure to psoriasis-modifying phototherapy or high-potency topical corticosteroid therapy within 2 weeks prior to the first dose of study drug
- Exposure to systemic anti-psoriatic therapy , topical immunomodulators or topical CNIs within 4 weeks prior to the first dose of study drug
- Current treatment with any therapy for tuberculosis
- Previous exposure to Alefacept
- Nursing mothers, pregnant women, and women planning to become pregnant during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Course A1
|
Intramuscular (IM)
Other Names:
|
|
Placebo Comparator: Course A2
|
Intramuscular (IM)
|
|
Experimental: Course B
Open label extension
|
Intramuscular (IM)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of patients achieving a Psoriasis Area and Severity Index (PASI) score of ≥ 50
Time Frame: 14 Weeks
|
14 Weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of patients achieving a PASI score of ≥ 50 any time during study
Time Frame: Throughout study
|
Throughout study
|
|
Proportion of patients achieving a PASI score of ≥ 75
Time Frame: 14 Weeks
|
14 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- C-740
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.